 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX  Free Report)  Stock analysts at HC Wainwright dropped their FY2023 EPS estimates for Kiora Pharmaceuticals in a note issued to investors on...

HC Wainwright Weighs in on Kiora Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:KPRX)

Encinitas, California--(Newsfile Corp. - November 9, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ('Kiora' or the 'Company') today announced its third quarter 2023 financial results and is...

Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Kiora Pharmaceuticals price target raised to $3.50 from $2 at H.C. Wainwright

Topline Phase I/II First-in-Human Results Presented at AAO 2023Significant improvement in visual field, in concordance with trended improvements in visual acuity and functional visionFunctional MRI...

AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa

Encinitas, California--(Newsfile Corp. - October 16, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation from the Lytham Partners Fall 2023...

Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference

Kiora Pharmaceuticals (NASDAQ:KPRX  Get Free Report) and PLx Pharma (NASDAQ:PLXP  Get Free Report) are both small-cap medical companies, but which is the superior stock? We will...

Analyzing Kiora Pharmaceuticals (NASDAQ:KPRX) and PLx Pharma (NASDAQ:PLXP)

Encinitas, California--(Newsfile Corp. - October 3, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) has received Investigational New Drug Application approval in Australia to enroll up to six additional...

Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa

Encinitas, California--(Newsfile Corp. - September 21, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced that its board of directors has appointed Praveen Tyle, PhD, who currently serves...

Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years

Encinitas, California--(Newsfile Corp. - September 18, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the completion of the final patient's last endpoint evaluation from the ABACUS...

Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa

Encinitas, California--(Newsfile Corp. - September 14, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ('Kiora' or the 'Company') announced that results from the ABACUS study of KIO-301 in...

Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

Watchers	4,184
52-Wk Low	$0.4622
52-Wk High	$8.52

Market Cap	$4.15M
Volume (M)	102,555.00
52-Wk High	$8.52
52-Wk Low	$0.4622

KPRX Kiora Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals